Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM) Read more about Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
Supernus Pharmaceuticals Reports Second Quarter 2013 Financial Results Read more about Supernus Pharmaceuticals Reports Second Quarter 2013 Financial Results
Supernus Sues Watson for Infringement of Oxtellar XR(TM) Patents Read more about Supernus Sues Watson for Infringement of Oxtellar XR(TM) Patents
Supernus Announces Second Quarter 2013 Earnings Conference Call and Webcast Read more about Supernus Announces Second Quarter 2013 Earnings Conference Call and Webcast
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(TM) Read more about Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(TM)
Supernus Receives Tentative Approval for Trokendi XR(TM) Read more about Supernus Receives Tentative Approval for Trokendi XR(TM)
Supernus to Present at Two Investor Conferences Read more about Supernus to Present at Two Investor Conferences
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results Read more about Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results
Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast Read more about Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019 Read more about Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019